A Phase 3 interventional study of Amlodipine 2.5mg/Atorvastatin 5mg and Amlodipine 2.5mg/Atorvastatin 10mg in Hypertension and Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 17 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 97th largest by enrollment of the 186 interventional ones that give a count, is one of 17 that started in 2007, is one of 69 in phase 3, and was the 47th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 20 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
34 studies in Hypertension by Viatris Inc.: none open now, none under way, none of them phase 3. Of 34 finished, 11 (32%) have results posted.
Among the 34 studies in Hypertension by Viatris Inc., this one is the 22nd largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2007, is one of 13 in phase 3, and was the 24th registered.
Viatris Inc.’s Hypertension studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
Among Viatris Inc.’s 34 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the changes in the trough Systolic Blood Pressure (SBP) and the percent changes in Low Density Lipoprotein-Cholesterol (LDL-C) from baseline at Week 8 in the treatment period
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Amlodipine 2.5mg/Atorvastatin 5mg
Drug: Amlodipine 2.5mg/Atorvastatin 10mg
Drug: Amlodipine 5mg/Atorvastatin 5mg
Drug: Amlodipine 5mg/Atorvastatin 10mg
Drug page: AmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Single pill combination, dosed once daily for 8 weeks
Drug page: AmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Single pill combination, dosed once daily for 8 weeks
Drug page: AmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Single pill combination, dosed once daily for 8 weeks
Drug page: AmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Single pill combination, dosed once daily for 8 weeks
Change in Systolic Blood Pressure
Value at Week 8 minus value at baseline
Time frame: 8 weeks
Percent Change in Low Density Lipoprotein-Cholesterol
Percent of "value at Week 8 minus value at baseline" over value at baseline
Time frame: 8 weeks
Change in Systolic Blood Pressure From Baseline to Each Observation Point
Value at Week 2, Week 4, or Week 8 minus value at baseline
Time frame: 2 weeks, 4 weeks, and 8 weeks
Change in Diastolic Blood Pressure From Baseline to Each Observation Point
Value at Week 2, Week 4, or Week 8 minus value at baseline
Time frame: 2 weeks, 4 weeks , and 8 weeks
Percent Change in Low Density Lipoprotein-Cholesterol From Baseline to Each Observation Point
Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline
Time frame: 2 weeks, 4 weeks , and 8 weeks
Percent Change in Total Cholesterol From Baseline to Each Observation Point
Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline
Time frame: 2 weeks, 4 weeks , and 8 weeks
Percent Change in High Density Lipoprotein-Cholesterol From Baseline to Each Observation Point
Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline
Time frame: 2 weeks, 4 weeks , and 8 weeks
Percent Change in Triglycerides From Baseline to Each Observation Point
Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline
Time frame: 2 weeks, 4 weeks , and 8 weeks
Change in Low Density Lipoprotein-Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (LDL-C/HDL-C) From Baseline to Each Observation Point
Value at Week 2, Week 4, or Week 8 minus value at baseline
Time frame: 2 weeks, 4 weeks, and 8 weeks
Change in Total Cholesterol/ High Density Lipoprotein-Cholesterol Ratio (TC/HDL-C) From Baseline to Each Observation Point
Value at Week 2, Week 4, or Week 8 minus value at baseline
Time frame: 2 weeks, 4 weeks , and 8 weeks
Change in Apolipoprotein B From Baseline to Each Observation Point
Value at Week 2, Week 4, or Week 8 minus value at baseline
Time frame: 2 weeks, 4 weeks, and 8 weeks
Twenty (20) centers in Japan
| Milestone | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg |
|---|---|---|---|---|
| Started | 43 | 41 | 41 | 40 |
| Completed | 41 | 39 | 40 | 38 |
| Not completed | 2 | 2 | 1 | 2 |
| Withdrew: Adverse event | 1 | 2 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Noncompliance | 1 | 0 | 0 | 0 |
Value at Week 8 minus value at baseline
| mm Hg | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg |
|---|---|---|---|---|
| Change in Systolic Blood Pressure | -16.6 ± 1.65 | -15.9 ± 1.69 | -21.8 ± 1.69 | -18.9 ± 1.71 |
Percent of "value at Week 8 minus value at baseline" over value at baseline
| Percent Change | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg |
|---|---|---|---|---|
| Percent Change in Low Density Lipoprotein-Cholesterol | -37.2 ± 1.49 | -42.5 ± 1.52 | -34.3 ± 1.52 | -40.6 ± 1.54 |
Value at Week 2, Week 4, or Week 8 minus value at baseline
| mm Hg | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg |
|---|---|---|---|---|
| Week 2 | -12.8 ± 9.63 | -13.5 ± 10.18 | -19.2 ± 10.53 | -16.0 ± 9.01 |
| Week 4 | -14.2 ± 10.26 | -14.6 ± 12.33 | -20.2 ± 11.08 | -19.6 ± 11.03 |
| Week 8 | -16.8 ± 11.40 | -15.3 ± 11.59 | -21.3 ± 10.07 | -18.7 ± 11.24 |
Value at Week 2, Week 4, or Week 8 minus value at baseline
| mm Hg | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg |
|---|---|---|---|---|
| Week 2 | -4.9 ± 6.23 | -6.0 ± 6.05 | -8.1 ± 6.24 | -8.2 ± 6.38 |
| Week 4 | -5.3 ± 4.96 | -8.2 ± 7.13 | -9.4 ± 6.19 | -9.2 ± 6.62 |
| Week 8 | -7.7 ± 6.34 | -8.7 ± 8.06 | -12.0 ± 6.31 | -9.9 ± 6.57 |
Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline
| Percent Change | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg |
|---|---|---|---|---|
| Week 2 | -34.8 ± 9.11 | -42.5 ± 11.00 | -32.8 ± 9.15 | -40.2 ± 13.52 |
| Week 4 | -37.4 ± 7.67 | -43.8 ± 9.30 | -35.0 ± 9.19 | -41.8 ± 9.53 |
| Week 8 | -37.6 ± 7.80 | -42.9 ± 10.28 | -34.2 ± 9.22 | -40.8 ± 11.28 |
Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline
| Percent Change | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg |
|---|---|---|---|---|
| Week 2 | -24.2 ± 6.86 | -30.5 ± 8.44 | -23.0 ± 7.22 | -28.3 ± 10.04 |
| Week 4 | -26.6 ± 6.36 | -31.5 ± 7.08 | -24.7 ± 7.64 | -28.6 ± 7.44 |
| Week 8 | -26.1 ± 6.01 | -30.0 ± 8.43 | -23.4 ± 7.78 | -28.2 ± 8.73 |
Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline
| Percent Change | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg |
|---|---|---|---|---|
| Week 2 | 7.7 ± 12.11 | 8.3 ± 10.70 | 6.6 ± 9.12 | 9.9 ± 10.32 |
| Week 4 | 7.2 ± 8.16 | 7.9 ± 13.03 | 9.3 ± 13.24 | 11.9 ± 13.28 |
| Week 8 | 7.2 ± 10.86 | 7.5 ± 13.27 | 9.7 ± 10.59 | 10.8 ± 9.66 |
Percent of "value at Week 2, Week 4, or Week 8 minus value at baseline" over value at baseline
| Percent Change | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg |
|---|---|---|---|---|
| Week 2 | -15.1 ± 33.82 | -27.4 ± 22.48 | -16.2 ± 20.00 | -23.9 ± 24.51 |
| Week 4 | -14.2 ± 25.31 | -25.7 ± 18.15 | -15.1 ± 22.42 | -23.2 ± 28.55 |
| Week 8 | -14.1 ± 19.72 | -21.1 ± 21.68 | -10.8 ± 31.42 | -24.0 ± 25.15 |
Value at Week 2, Week 4, or Week 8 minus value at baseline
| Ratio | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg |
|---|---|---|---|---|
| Week 2 | -1.2 ± 0.58 | -1.4 ± 0.42 | -1.1 ± 0.49 | -1.3 ± 0.53 |
| Week 4 | -1.3 ± 0.41 | -1.4 ± 0.42 | -1.2 ± 0.56 | -1.4 ± 0.49 |
| Week 8 | -1.2 ± 0.37 | -1.4 ± 0.44 | -1.2 ± 0.52 | -1.4 ± 0.52 |
Value at Week 2, Week 4, or Week 8 minus value at baseline
| Ratio | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg |
|---|---|---|---|---|
| Week 2 | -1.3 ± 0.71 | -1.6 ± 0.49 | -1.2 ± 0.61 | -1.5 ± 0.64 |
| Week 4 | -1.4 ± 0.48 | -1.6 ± 0.49 | -1.4 ± 0.69 | -1.6 ± 0.59 |
| Week 8 | -1.3 ± 0.43 | -1.5 ± 0.51 | -1.4 ± 0.65 | -1.5 ± 0.62 |
Value at Week 2, Week 4, or Week 8 minus value at baseline
| mg/dL | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg |
|---|---|---|---|---|
| Week 2 | -36.6 ± 12.55 | -45.8 ± 12.11 | -33.5 ± 9.86 | -44.4 ± 15.46 |
| Week 4 | -40.1 ± 10.94 | -47.2 ± 10.20 | -36.6 ± 11.36 | -45.8 ± 13.79 |
| Week 8 | -40.2 ± 9.65 | -46.4 ± 10.87 | -36.6 ± 12.27 | -45.1 ± 14.39 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CI-1038 2.5 mg/5 mg | — | 0/43 (0%) | 6/43 (14%) |
| CI-1038 2.5 mg/10 mg | — | 0/41 (0%) | 7/41 (17.1%) |
| CI-1038 5 mg/5 mg | — | 0/41 (0%) | 8/41 (19.5%) |
| CI-1038 5 mg/10 mg | — | 0/40 (0%) | 8/40 (20%) |
| Event | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/43 | 3/41 | 5/41 | 7/40 |
| NauseaGastrointestinal disorders | 0/43 | 2/41 | 0/41 | 0/40 |
| Seasonal AllergyImmune system disorders | 0/43 | 0/41 | 2/41 | 0/40 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 0/43 | 2/41 | 1/41 | 0/40 |
| HeadacheNervous system disorders | 0/43 | 2/41 | 0/41 | 1/40 |
| Age, Customized(participants) | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg | Total |
|---|---|---|---|---|---|
| <20 years | 0 | 0 | 0 | 0 | 0 |
| 20 to 44 years | 8 | 3 | 4 | 5 | 20 |
| 45 to 64 years | 20 | 21 | 23 | 23 | 87 |
| >=65 years | 15 | 17 | 14 | 12 | 58 |
| Sex: Female, Male(Participants) | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg | Total |
|---|---|---|---|---|---|
| Female | 23 | 28 | 25 | 22 | 98 |
| Male | 20 | 13 | 16 | 18 | 67 |
| Region of Enrollment(participants) | CI-1038 2.5 mg/5 mg | CI-1038 2.5 mg/10 mg | CI-1038 5 mg/5 mg | CI-1038 5 mg/10 mg | Total |
|---|---|---|---|---|---|
| Japan | 43 | 41 | 41 | 40 | 165 |
The record gives a start of Sep 2007, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2009, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlodipine
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →